Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Phase 3 Completed 291 enrolled Merck Sharp & Dohme LLC Pfizer · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in combination with sitagliptin in the treatment of participants with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise. The primary hypothesis of the study is that ertugliflozin plus sitagliptin is more effective in lowering of hemoglobin A1C (HbA1C) than placebo.

Timeline

Start: 2014-09-23
Primary completion: 2016-02-23
Completion: 2016-02-23

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ertugliflozin	Unknown	5 mg	Oral
Subject	Ertugliflozin	Unknown	15 mg	Oral
Subject	Sitagliptin	Small molecule	100 mg	Oral
Background	Glimepiride	Small molecule	1 mg	Oral
Background	Glimepiride	Small molecule	2 mg	Oral

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Summary

Timeline

Publications

Drugs

Indications